A12AA07 calcium chloride
ALIMENTARY TRACT AND METABOLISM ›MINERAL SUPPLEMENTS ›CALCIUM ›Calcium
健保收載品項 TFDA 在效許可證 4 FDA 已核准 健保給付條款 2
台灣藥品與外觀
健保收載品名:葡萄糖鈣注射液
資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 暫時緩解因眼睛乾澀所引起的灼熱感與刺激感。暫時緩解因配戴隱形眼鏡造成之不適。
- 鈣離子補充藥。
美國 FDA 適應症(英文原文對照)
6B7800S 12x 800 mL Rx only Store at Controlled Room Temperature. Protect from freezing. Avoid excessive heat. Definition of "Controlled Room Temperature": "A temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15°C and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses. Provided the mean kinetic temperature remains in the allowed range, transient spikes up to 40°C are permitted as long as they do not exceed 24 hours ... The mean kinetic temperature is a calculated value that may be used as an isothermal storage temperature that simulates the non isothermal effects of storage temperature variations." Reference: United States Pharmacopeia, General Notices. United States Pharmacopeial Convention, Inc. 12601 Twinbrook Parkway, Rockville, MD. Dispose of waste in appropriate biohazard container or according to local regulatory requirements. Indications and Usage: InterSol solution is an isotonic solution designed to replace a proportion of the plasma used in the storage of leukoreduced apheresis platelets under standard blood banking conditions. There is no direct therapeutic effect to be expected from the formulation. The solution should never be infused directly into a patient. InterSol platelets are leukocyte-reduced apheresis platelet concentrates that are stored in a mix of 65% InterSol and 35% plasma, nominal. InterSol platelets prepared within the ranges described in the apheresis system Operator's Manuals may be stored for up to 5 days at 20-24°C, with continuous agitation.
資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。
健保給付規定
直接適用條款
§ 3.1.1 Fat emulsion:或含Fat emulsion 之靜脈營養輸液(如含glucose、lipid、
代謝及營養劑 › 靜脈營養輸液
Fat emulsion:或含Fat emulsion之靜脈營養輸液(如含glucose、lipid、amino acid及electrolytes三合一靜脈營養輸液):(97/11/1、98/7/1、98/12/1) 限 1.嚴重燒傷病人,為靜脈營養補充。 2.使用全靜脈營養者。 3.重大手術後五至七天仍不能經腸道進食者,每日不超過一瓶為原則。(98/12/1)
歷史演變(3 次異動)
| 生效日 | 異動說明 |
|---|---|
| 97/11/1 | legacy_boan_parsed:ch03.txt |
| 98/7/1 | legacy_boan_parsed:ch03.txt |
| 98/12/1 | legacy_boan_parsed:ch03.txt |
上層 ATC 繼承條款
繼承自 ATC A12AA
§ 3.3.4 口服鈣質補充劑oral calcium salt:(89/2/1)
代謝及營養劑 › 其他
口服鈣質補充劑oral calcium salt:(89/2/1) 限下列病患使用: 1.骨質疏鬆(osteoporosis)或軟骨病(osteomalacia)病患。 2.高磷酸鹽血症(hyperphosphatemia)或低血鈣症(hypocalcemia)。 3.長期使用糖皮質類固醇(glucocorticoid)病患。 4.腎衰竭病患。
歷史演變(1 次異動)
| 生效日 | 異動說明 |
|---|---|
| 89/2/1 | legacy_boan_parsed:ch03.txt |
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。